Akero Therapeutics (NASDAQ:AKRO) released its quarterly earnings results on Tuesday. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13), Bloomberg Earnings reports.
Shares of AKRO traded down $0.30 on Friday, hitting $19.67. 965 shares of the stock traded hands, compared to its average volume of 66,565. The firm has a 50 day moving average price of $20.41. Akero Therapeutics has a 1 year low of $16.06 and a 1 year high of $30.30.
Separately, Zacks Investment Research lowered shares of Akero Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $31.25.
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
Further Reading: What Are Treasury Bonds?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.